HC Wainwright Reaffirms “Buy” Rating for Sangamo Therapeutics (NASDAQ:SGMO)

HC Wainwright reissued their buy rating on shares of Sangamo Therapeutics (NASDAQ:SGMO) in a research report sent to investors on Wednesday morning, Benzinga reports. They currently have a $5.00 price target on the biopharmaceutical company’s stock.

Separately, StockNews.com assumed coverage on shares of Sangamo Therapeutics in a research note on Sunday, July 28th. They issued a sell rating for the company. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of Hold and an average target price of $5.67.

Sangamo Therapeutics Trading Up 23.6 %

SGMO stock opened at $0.87 on Wednesday. The company has a 50 day simple moving average of $0.51 and a 200 day simple moving average of $0.62. Sangamo Therapeutics has a 1 year low of $0.29 and a 1 year high of $1.48.

Sangamo Therapeutics (NASDAQ:SGMO) last issued its quarterly earnings data on Thursday, May 9th. The biopharmaceutical company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.22) by ($0.05). The company had revenue of $0.48 million during the quarter, compared to the consensus estimate of $8.51 million. Sangamo Therapeutics had a negative net margin of 1,749.06% and a negative return on equity of 182.55%. During the same period in the previous year, the company earned $0.12 EPS. Research analysts forecast that Sangamo Therapeutics will post -0.55 EPS for the current fiscal year.

Hedge Funds Weigh In On Sangamo Therapeutics

Several large investors have recently modified their holdings of SGMO. Mackenzie Financial Corp raised its stake in shares of Sangamo Therapeutics by 72.4% during the fourth quarter. Mackenzie Financial Corp now owns 73,799 shares of the biopharmaceutical company’s stock valued at $40,000 after acquiring an additional 31,003 shares during the last quarter. State Board of Administration of Florida Retirement System raised its stake in shares of Sangamo Therapeutics by 61.1% during the first quarter. State Board of Administration of Florida Retirement System now owns 62,345 shares of the biopharmaceutical company’s stock valued at $42,000 after acquiring an additional 23,650 shares during the last quarter. Golden State Equity Partners raised its stake in shares of Sangamo Therapeutics by 21.0% during the fourth quarter. Golden State Equity Partners now owns 201,225 shares of the biopharmaceutical company’s stock valued at $109,000 after acquiring an additional 34,960 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Sangamo Therapeutics during the first quarter worth $331,000. Finally, Assenagon Asset Management S.A. increased its position in shares of Sangamo Therapeutics by 14.4% during the fourth quarter. Assenagon Asset Management S.A. now owns 1,033,322 shares of the biopharmaceutical company’s stock worth $561,000 after buying an additional 129,811 shares during the period. Institutional investors own 56.93% of the company’s stock.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.